STOCK TITAN

Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Poseida Therapeutics (Nasdaq: PSTX) announced participation in two upcoming virtual investor conferences. Eric Ostertag, CEO, will speak at the Raymond James Cell Therapy for Oncology Symposium on April 22, 2021, discussing the manufacturing of off-the-shelf cell-based therapy. Additionally, he will host a Fireside Chat at the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021. Webcasts are available on Poseida's website, with replay options for around 30 days.

Positive
  • None.
Negative
  • None.

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company will participate in the following upcoming virtual investor conferences:

Raymond James Cell Therapy for Oncology Symposium
Start-up to Scale-up: A Discussion on Manufacturing of Off The Shelf Cell Based Therapy
Panel discussion with Poseida CEO Eric Ostertag, MD, PhD
Thursday, April 22, 2021
9:00am ET

7th Annual Truist Securities 2021 Life Sciences Summit
Fireside Chat with Poseida CEO Eric Ostertag, MD, PhD
Wednesday, May 5, 2021
3:30pm ET

Webcasts will be available on the Investors & Media Section of the Poseida website, www.poseida.com.  An archived replay of each webcast will be available for approximately 30 days following each presentation. 

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit www.poseida.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential benefits of Poseida's technology platforms and product candidates, Poseida's plans and strategy with respect to developing its technologies and product candidates and anticipated timelines and milestones with respect to Poseida's development programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-upcoming-virtual-investor-conferences-301264549.html

SOURCE Poseida Therapeutics, Inc.

FAQ

What are the upcoming virtual investor conferences for PSTX?

Poseida Therapeutics will participate in the Raymond James Cell Therapy for Oncology Symposium on April 22, 2021, and the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021.

Who will represent PSTX at the investor conferences?

CEO Eric Ostertag, MD, PhD, will represent Poseida Therapeutics at both conferences.

When is the Raymond James Symposium featuring PSTX?

The Raymond James Cell Therapy for Oncology Symposium is scheduled for April 22, 2021, at 9:00 am ET.

When can I watch the PSTX Fireside Chat?

The Fireside Chat with CEO Eric Ostertag at the Truist Securities Summit will take place on May 5, 2021, at 3:30 pm ET.

Where can I access webcasts for PSTX's investor conferences?

Webcasts for the conferences will be available on Poseida Therapeutics' Investors & Media section of their website at www.poseida.com.

Poseida Therapeutics, Inc.

NASDAQ:PSTX

PSTX Rankings

PSTX Latest News

PSTX Stock Data

271.93M
70.29M
27.64%
55.75%
4.52%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO